Favipiravir is currently under investigation for use in the treatment of Coronavirus disease (COVID19)
Women of child-bearing age confirmed negative pregnancy test before use.
Men: use effective contraception during and for 7days post-treatment (drug is distributed in sperm )
Pyrazinamide: Favipiravir may enhance the adverse /toxic effects of Pyrazinamide, the risk for increased uric acid concentrations, recommended: Monitor therapy
Repaglinide: Favipiravir may increase the serum concentration of repaglinide, recommended: Monitor therapy.
Oral absorption: No data
Average serum half-life: 5.6hr
Elimination: Metabolized by aldehyde oxidase and xanthine oxidase to hydroxylated metabolite eliminated in the urine
CSF /Blood penetration: No data
Biliary penetration: No data
Pregnancy: Avoid use. Teratogenic
Breastfeeding: Contraindicated